Trials / Recruiting
RecruitingNCT07116616
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 166 (estimated)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mRNA-2808 | intravenous |
Timeline
- Start date
- 2025-09-30
- Primary completion
- 2030-06-17
- Completion
- 2032-06-17
- First posted
- 2025-08-11
- Last updated
- 2026-04-03
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07116616. Inclusion in this directory is not an endorsement.